Stay updated with breaking news from Pharma Two. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A phase 3 study evaluating a novel fixed-dose combination of extended release pramipexole and rasagiline (P2B001) in adults with early Parkinson disease met its primary and key secondary endpoints.
A phase 3 study evaluating a novel fixed-dose combination of extended release pramipexole and rasagiline (P2B001) in adults with early Parkinson disease met its primary and key secondary endpoints.
/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...
/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...
/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...